GLP-1 secretion in patients with type 2 diabetes GLP-1 hypersecretion was described in some early studies [18, 49] in response to the ingestion of oral glucose, probably related to the use of side-viewing antibodies, which also detect the major proglucagon fragment [50]
DPP-4 inhibitors, known as gliptins, are a class of oral diabetic medications to treat type 2 diabetes mellitus in adults
Rossi, A
Glutathione: overview of its protective roles, measurement and biosynthesis
The Wegovy-vs-Zepbound gap is consistent with mechanism: Wegovy activates only the GLP-1 receptor at a high obesity-management dose, while tirzepatide adds GIP receptor activity that may modestly buffer some GI effects
Lo nico que quiero demostrar es que no desayunar no tiene inconvenientes como muchos dicen, y que nuestros desayunos actuales pueden ser un factor importante en temas de sobrepeso o diabetes